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 Spontaneously diabetic Torii (SDT) rats are models of
type 2 diabetes [1]. They develop hyperglycemia and glyco-
suria spontaneously at about 20-weeks-of-age but can survive
for a long time without insulin treatment. More important, SDT
rats exhibit severe ocular complications, such as tractional
retinal detachment, which resembles proliferative diabetic re-
tinopathy (PDR) in humans.
We recently reported that neovascularization of retinal ves-
sels was present in some SDT rats with tractional retinal de-
tachments and proliferative tissues, but the incidence was low.
Non-perfused areas that indicated the presence of ischemic
areas of the retina were not detected at all ages [2]. The low
incidence of neovascular formation and absence of capillary
occlusion in the retina make the SDT rat model different from
the findings in typical PDR in humans. Interestingly, the ex-
pressions of pigment epithelium-derived factor (PEDF), a
strong inhibitor of ocular angiogenesis, and vascular endothe-
lial growth factor (VEGF), a strong stimulator of angiogen-
esis, were both up-regulated in the SDT rat retinas [2]. These
findings are different from the low levels of PEDF in human
eyes with diabetic retinopathy or in eyes with ischemia-in-
duced retinal neovascularization [3-9].
Diabetic retinal neovascularization is considered to be a
result of retinal ischemia caused by capillary occlusion. Leu-
kocytic activation and the adhesion of leukocytes to the vas-
cular endothelial cells initiate capillary occlusion in diabetic
retinopathy [10,11]. Strong interactions between leukocytes
and endothelial cells are governed by intracellular adhesion
molecule (ICAM)-1 [12,13]. Increased levels of circulating
soluble ICAM-1 (sICAM-1) are considered to be a risk factor
for obstructive cardiovascular disease [14-16] and also for the
progression of diabetic retinopathy [17].
We have shown that levels of both PEDF and VEGF in
the retina of SDT rat are elevated [2]. Thus, the aim of this
study was to determine the levels of PEDF and sICAM-1 in
the blood of SDT rats, and to examine the effects of PEDF on
the adhesion of leukocytes to endothelial cells.
METHODS
Animals:  The Committee of Animal Use of the Kansai Uni-
versity Medical School approved the experimental protocol,
which also followed the ARVO guidelines for care and use of
animals in eye research.
SDT rats (Tobacco Inc., Toxicology Research Laborato-
ries, Kanagawa, Japan) and streptozotocin-induced diabetic
rats (STZ) [11,18] were used. Normal Sprague Dawley (SD)
rats were used as controls. SDT rats were defined as having
diabetes if a dipstick test (Bayer Co., Tokyo, Japan) showed
their urinary glucose level to be 3+ or higher. None of the
SDT rats required insulin treatment. Diabetes was induced in
20 week-old SD rats with a single 60 mg/kg intraperitoneal
injection of streptozotocin (STZ, Sigma, St. Louis, MO)
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Purpose: Spontaneously diabetic Torii (SDT) rats, an animal model of type 2 diabetes, have a low incidence of neovascular
formation and an absence of non-perfused areas in their retinas at the proliferative stage that presents tractional retinal
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Results: SDT and STZ diabetic rats showed a significant increase of retinal leukostasis compared to that of control SD
rats, but SDT rats had noteworthy lower levels of leukostasis than STZ rats in long term experiments. The sICAM-1 levels
and PEDF expression were up-regulated in both STZ and SDT rats, but the SDT rats showed significantly higher levels of
PEDF than STZ rats. In vitro studies showed that exposure of HUVECs to VEGF increased the number of adhering
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1058[11,18]. Animals whose blood glucose levels were greater than
250 mg/dl at 48 h after the streptozotocin injection were clas-
sified as being diabetic. All animals were maintained in stan-
dardized housing with free access to water and standard labo-
ratory chow.
Body weight and blood samples:  Each rat’s body weight,
blood glucose level, and glycosuria were measured at regular
intervals. Two study periods were selected; 24 weeks for the
short term effects of diabetes mellitus (DM), and 40 weeks
for the long term effects. We used 8 eyes of 8 rats in each
group at each study period in the experiments. At the end of
every study period, blood samples were collected from each
rat’s jugular vein before the animal was euthanized. The plasma
glucose level was measured by the glucose oxidase method
using Glucose-Test Wako® (Wako Pure Chemical Co., Osaka,
Japan).
Index of retinal leukostasis:  The retinal vasculature and
adherent leukocytes were labeled with FITC-conjugated con-
canavalin A lectin (Con A: Vector Labs, Burlingame, CA) us-
ing a slight modification of a published perfusion-labeling tech-
nique [11,18,19]. Briefly, rats were anesthetized with an over-
dose of ketamine (50 mg/kg) intraperitoneally, then the rats
were perfused with 250 ml/kg body weight of phosphate buff-
ered saline (PBS) over 2 min to remove erythrocytes and non-
adherent leucocytes. The eyes were enucleated and fixed in
2% paraformaldehyde for 1 h. Retinas were isolated, and flat
mounts were prepared using an anti-fading fluorescence me-
dium (Southern Biotechnology, Birmingham, AL). The reti-
nal vessels were then examined with a fluorescence micro-
scope (BX50, Olympus, Tokyo, Japan). Leukocytes in the reti-
nal arterioles, venules, and capillaries were counted by two
masked observers, and the total was used as an index of reti-
nal leukostasis.
To confirm that the cells adhering to the vessels were leu-
kocytes, were performed immunofluorescence with CD45, a
leukocytes markers. After the adherent leukocytes were la-
beled with FITC-conjugated Con A, the flat-mounted retinas
were permeabilized in 0.5% Triton X-100 (Sigma) in PBS for
24 h, then incubated overnight at 4 °C with a phycoerythrin-
conjugated mouse monoclonal antibody against rat CD45
(1:200 dilution; Chemicon International Inc., Temecula, CA).
The tissues were mounted, and the retinas were examined as
described in the previous paragraph.
Pigment epithelium-derived factor expression in plasma:
PEDF levels in the plasma were measured by Western blot
analysis from collected blood samples as described [2]. Band
intensity was analyzed by gel plotting macro (NIH image Ver-
sion 1.62, Mac OS9).
Soluble intracellular adhesion molecule-1 levels in
plasma:  Plasma sICAM-1 levels were measured by an ELISA
Kit (Quantkine® ICAM-1 ELISA Kit, R&D systems Inc., Min-
neapolis, MN), according to the manufacturer’s protocol.
Monocyte adhesion assay:  Human monocytes were iso-
lated from fresh, heparinized blood by density centrifugation
using Ficoll-Paque Plus (Amersham Biosciences, Baied’Urfe,
Quebec, Canada) according to the manufacturer’s protocol.
The blood was collected from healthy volunteers after we ob-
tained informed consent. A published technique for calcein-
AM-labeling (Dojindo Lab., Kumamoto, Japan) was used with
slight modification [20,21]. The viability of the monocytes
was assessed by the trypan blue exclusion test and was al-
ways >90%.
Human umbilical vein endothelial cells (HUVECs:
Dainippon Pharmaceutical Co., LTD., Osaka, Japan) grown
to confluence on collagen type I coated culture slides (BD
Biosciences), were treated with VEGF165 (20 ng/ml in the
medium, R&D Systems Inc.) as well as PEDF (0, 10, and 100
ng/ml in the medium, Chemicon International, Temecula, CA)
for 24 h. Following the treatment, calcein AM-labeled mono-
cytes (1.5x106/ml, 200 µl/well) were added to the HUVECs
and incubated for 60 min at 37 °C. Immediately before the
assay, non-adherent cells were removed by washing four times
with RPMI-1640 medium (Cat No. R8753, Sigma-Aldrich
Japan K.K., Tokyo, Japan). The cells were then fixed for 30
min in 3.7% formaldehyde neutral buffer solution (Sigma-
Aldrich Japan K.K., Tokyo, Japan) for 30 min at room tem-
perature. The adherent monocytes were labeled with
rhodamine-conjugated concanavalin A lectin (40 µg/ml in PBS,
pH7.4, Vector Labs). The images were captured with a fluo-
rescence microscope and images were captured in digital for-
mat.
Statistical analyses:  The results were expressed as
mean±standard error of the means (SEM), and the data were
analyzed using the one way analysis of variance (ANOVA)
with Fisher’s the least significant difference (LSD) when com-
paring groups. A p value of <0.05 was accepted as significant.
RESULTS
Index of retinal leukostasis:  Leukocytes adhering to the reti-
nal vessels in control SD rats (Figure 1A,D,G), STZ rats (Fig-
ure 1B,E,H), and in SDT rats (Figure 1C,F,I) were counted
while being viewed in whole mounts of the retina under con-
focal fluorescence microscopy. The retinal vasculature and
adhering leukocytes were labeled green with FITC-conjugated
concanavalin A lectin (Figure 1A-C), and the leukocytes were
labeled red with phycoerythrin-conjugated CD45 antibody
(Figure 1D-F). The leukocytes adhering to the vessel appeared
yellow in the merged images (Figure 1G-I).
The number of adherent leukocytes was significantly
higher in STZ rats than in the control SD rats in the short term
experiments (13.2±4.8 cells/retina vs 4.5±2.2 cells/retina,
p<0.05) and in the long term experiments (21.2±2.2 cells/retina
versus 6.5±3.0 cells/retina, p<0.05). These findings indicate
that the number of adherent leukocytes, and thus the index of
retinal leukostasis, increased significantly with the duration
of diabetes (p<0.05; Figure 1J).
The SDT rats also showed a significant increase in the
index of retinal leukostasis to that of controls in the short term
experiments (12.0±3.0 cells/retina; p<0.05) and in the long
term experiments (15.5±3.2 cells/retina; p<0.05), but the in-
crease was not significant with the duration of diabetes
(p<0.05). An important difference was that the index of reti-
nal leukostasis was lower in SDT rats than in STZ rats in the
long-term experiments (p<0.05, Figure 1J).
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1059Increased plasma pigment epithelium-derived factor ex-
pression in diabetic rats:  When the expression of PEDF in
the STZ and SDT rats was compared to that of controls, it was
found there was a significant increase in PEDF in both STZ
(172% increase in short term, 180% increase in long term;
p<0.05, respectively) and SDT rats (264% increase in short
term, and 239% increase in long term; p<0.05, respectively).
PEDF levels were not significantly different between short
term and long-term experiments in control, STZ, and SDT
rats. An important difference was that the SDT rats had sig-
nificantly higher levels of PEDF compared to that of STZ rats
in both short term and long term diabetes (p<0.05 Figure 2).
Increased plasma soluble intracellular adhesion mol-
ecule-1 levels in diabetic rats:  In the long-term experiments,
the level of sICAM-1 was significantly higher in both the STZ
and SDT rats than in control SD rats (22.1±8.5 ng/ml, p<0.05).
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Figure 1. Adherent leukocytes in the retinal vasculature.  Confocal
fluorescence photographs of retinal vasculature and adherent leuko-
cytes in Sprague-Dawley (SD) rats as control (A, D, G),
streptozotocin-induced diabetic rats (STZ), which were spontaneously
diabetic Torii (SDT) rats: (B, E, H), and SDT rats (C, F, I). The
retinal vasculature and adherent leukocytes were stained green by
FITC-conjugated concanavalin A lectin (A, B, C), and the adherent
leukocytes were labeled with phycoerythrin-conjugated anti-rat CD45
antibody (D, E, F). The adherent leukocytes appear yellow in the
merges images (G, H, I). Scale bar equals 20 µm. J shows the Index
of retinal leukostasis. The adherent leukocytes were significantly in-
creased in STZ rats compared to that of control SD rats in short term
experiments (control vs STZ, p<0.05), and in long term experiments
(p<0.05). SDT rats in short term experiments (p<0.05), and in long
term experiments (p<0.05) also showed significantly increased ad-
herent leukocytes compared to that of controls. However, SDT in
long term experiments show significantly lower levels of leukostasis
compared to that of STZ rats. In addition, the adherent leukocytes
were significantly increased with duration of diabetes in STZ rats
(p<0.05), but SDT rats did not show the increase with duration of
diabetes. The data were analyzed by ANOVA. Asterisk equals p<0.05.
DM represents diabetes mellitus. Eight eyes are used in each group
at each study period.
1060For the short term experiments, the level of sICAM-1 in the
STZ and SDT diabetic rats was higher that that in the control
SD rats, but the difference was not significant. In STZ rats,
the sICAM-1 level was increased with an increase in the du-
ration of diabetes (34.6±5.0 ng/ml in short term experiments
versus 60.5±10.2 ng/ml in long term experiments, p<0.05).
Similar findings were found in the SDT rats with a sICAM-1
level of 39.4±9.0 ng/ml in the short term experiments and
68.2±6.1 ng/ml in the long term experiments (p<0.05). How-
ever, there was not a significant difference in the level of
sICAM-1 between the STZ and the SDT rats (Figure 3).
Effects of pigment epithelium-derived factor and vascu-
lar endothelial growth factor on monocytic adhesion tohuman
umbilical vein endothelial cells:  Monocytes and the nuclei of
HUVECs were labeled green with calcein-AM (Figure 4A),
and the cell surface of the monocytes and HUVECs were la-
beled red with rhodamine-conjugated Con-A lectin (Figure
4B). The adherent monocytes appeared yellow in the merged
images obtained by combining the FITC and rhodamine im-
ages (Figure 4C).
The monocyte adhesion assay was performed on HUVECs
treated with PBS as control (Figure 4D), with VEGF (20 ng/
ml, Figure 4E), with PEDF (100 ng/ml, Figure 4F), and with
PEDF + VEGF (Figure 4G) for 24 h. Exposure to PEDF did
not significantly alter the number of monocytes adhering to
HUVECs (119±24% increase) compared to that of controls.
Alternatively, when VEGF was added to the media, the num-
ber of adherent monocytes was significantly increased
(339±69%; p<0.01) compared to that of controls. When PEDF
was added with VEGF, the number of adherent monocytes
induced by VEGF dropped to 194±44% (p<0.01; n=8; Figure
4H).
When PEDF was combined with VEGF, PEDF appeared
to inhibit the increase of adherent monocytes in a dose depen-
dent manner (Figure 4I).
DISCUSSION
 The adhesion of leukocytes to the retinal capillary endothe-
lium has been shown to be an important event in animal mod-
els of diabetic retinopathy [11,22,23]. This adhesion plays a
significant role in the breakdown of the blood-retinal barrier
and in the occlusion of retinal capillaries [11]. ICAM-1 medi-
ates the adhesion of neutrophils and monocytes to the vascu-
lar endothelium, and increased ICAM-1 levels have been found
in the blood and in the retinal vasculature of patients with
diabetes [17,24].
Recently, we reported that diabetic retinopathy in SDT
rats is characterized by a low incidence of retinal
neovascularization and an absence of retinal capillary occlu-
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Figure 2. Western blot analysis for plasma pigment epithelium-de-
rived factor expression.  A: Data from 20-week-old control Sprague-
Dawley (SD) rats, short term diabetes mellitus (DM)-streptozotocin-
induced diabetic rats (S-STZ), short term DM-spontaneously dia-
betic Torii rats (S-SDT), and long term DM-SDT rats (L-SDT). The
expression of pigment epithelium-derived factor (PEDF) was con-
firmed with the presence of recombinant PEDF (positive control,
50-kDa). B: Statistical analysis for the PEDF expression. PEDF ex-
pression is significantly higher in STZ rats in both the short term and
long term experiments compared to that of SD rats. The expression
of PEDF is also significantly higher in SDT rats compared to that of
control (p<0.05). SDT rats had significantly higher levels of PEDF
compared to that of STZ rats in both short term and long term diabe-
tes mellitus. Data were analyzed by ANOVA with Fisher’s LSD.
Asterisk equals p<0.05. Eight eyes are used in each group at each
study period.
Figure 3. Plasma soluble intracellular adhesion molecule-1 levels.
The levels of soluble intracellular adhesion molecule-1 (sICAM-1)
were increased with duration of diabetes. The levels of sICAM-1 are
significantly higher in long term both streptozotocin-induced dia-
betic (STZ) rats and spontaneously diabetic Torii (SDT) rats than in
Sprague-Dawley (SD) rats (p<0.05), but the difference is not signifi-
cant between short term diabetic rats and controls. In addition, there
was not a significant difference in the level of sICAM-1 between the
STZ and the SDT rats. The data were analyzed by ANOVA with
Fisher’s LSD. Asterisk indicates p<0.05. Eight eyes are used in each
group at each study period.
1061sion [2]. The results of this study showed that leukostasis is
increased in both SDT and STZ diabetic rats compared to that
of controls. However, the index of leukostasis was significantly
lower in SDT rats than in STZ rats in long-term experiments.
STZ rats had a significant increase in the number of adherent
leukocytes with longer durations of diabetes but SDT rats did
not show this effect with the duration of the diabetes.
The plasma sICAM-1 levels were up-regulated in both
SDT and STZ rats, and the increase was greater in long-term
experiments. This is interesting because there was a signifi-
cant difference in the index of leukostasis between STZ and
SDT rats in the long tern experiments, although the sICAM-1
levels were not significantly different.
The plasma level of PEDF was increased in both SDT
and STZ rats compared to that of controls, and the increase in
the level of PEDF was significantly higher in SDT rats than in
STZ rats. PEDF has been shown to be a potent inhibitor of
angiogenesis [3]. The results of earlier studies have suggested
that a decrease in the level of PEDF in the eye is involved in
the pathogenesis of PDR in both animals and humans [4,5,8].
We have reported that the VEGF and PEDF levels in the retina
of SDT rats were both up-regulated by Western blotting and
immunohistochemistry [2]. Thus, higher levels of PEDF in
the eye and in the blood most likely contributed to the lack of
development of retinal neovascularization in SDT rats.
VEGF is a strong angiogenic factor and many previous
studies have demonstrated its involvement in diabetic retin-
opathy [19]. VEGF can increase the expression of ICAM-1
on capillary endothelial cells in vitro and on the retinal vascu-
lature in vivo [25,26]. Administration of PEDF has been shown
to effectively inhibit retinal neovascularization and to reduce
the VEGF-induced vascular hyperpermeability [7,27,28].
These results suggest that PEDF counteracts the effects of
VEGF on retinal neovascularization. However, the mechanism
for this inhibition has still not been determined. We hypoth-
esized that the higher levels of PEDF in the plasma counter-
acted the effect of VEGF and also contributed to the low lev-
els of leukostasis in SDT rats.
Our in vitro studies showed that VEGF increased the num-
ber of monocytes adherent to HUVECs, and this increase was
significantly reduced by PEDF. In addition, PEDF also sup-
pressed the VEGF-induced leukostasis in a dose-dependent
manner, and the effective concentration (10-100 ng/ml) was
lower than that for normal human subjects (5 µg/ml) [29]. We
found that serum levels of VEGF were up-regulated in both
SDT and STZ rats (unpublished data). VEGF-induced
leukostasis is linked to capillary non-perfusion and increased
vascular permeability [30]. Alternatively, PEDF can counter-
act VEGF-induced vascular permeability [28]. Although, reti-
nal endothelial cells may have properties somewhat different
from HUVECs, our results, together with the previous reports,
indicated that PEDF is more likely to act as an inhibitor of
VEGF function. Therefore, high levels of PEDF in the plasma
of SDT rats might inhibit the VEGF-induced leukostasis and
result in the absence of capillary occlusion and lower inci-
dence of retinal neovascularization. Additional studies are
needed to determine the molecular mechanism by which PEDF
inhibits VEGF.
PEDF can reduce VEGF activity and VEGF induced
leukostasis, but we found increased levels of sICAM-1 in SDT
rats. It is possible that PEDF may also directly counteract the
activity of ICAM-1. In diabetic retinas, when the VEGF bio-
activity is blocked, the up-regulation of ICAM-1, leukocyte
adhesion, and BRB breakdown are substantially reduced [19].
Chronic, low-grade inflammation is responsible for many of
the signature vascular lesions of diabetic retinopathy [18].
PEDF has been suggested to be an anti-inflammatory cytokine
[31], thus, high levels of PEDF in the retina and plasma may
inhibit inflammation in diabetic retinas.
The accumulation of advanced glycation end products
(AGEs) in the diabetic retina is also involved in retinal
leukostasis and microthrombosis by enhancing the expression
of adhesion molecules [32,33], inducing apoptosis of pericytes,
and up-regulating VEGF [34]. These changes then contribute
to focal ischemia in early diabetic retinopathy. Recently, it
was reported that PEDF prevented diabetes- or AGE-elicited
retinal leukostasis [35] and also inhibited AGE-induced cell
death of pericytes [36] and monocyte chemoattractant pro-
tein-1 production in microvascular endothelial cells [37]. These
activities of PEDF on AGE may also contribute to reduction
of leukostasis.
In conclusion, PEDF inhibits VEGF-induced leukostasis
in vitro, and this action most likely explains the low incidence
of capillary occlusion and retinal neovascularization in SDT
rats. These findings suggest that PEDF should be examined
as a possible therapeutic agent for the treatment of diabetic
retinopathy.
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Figure 4 (next page). Confocal fluorescence microscopy for detection of adherent monocytes to human umbilical vein endothelial cells.
Monocytes and nuclei of human umbilical vein endothelial cells (HUVECs) were labeled in green with Calcein-AM (A). The cell surfaces of
the monocytes and HUVECs were labeled red with rhodamine-conjugated Con-A lectin (B). Adherent monocytes appeared yellow in the
merged images obtained by combining FITC and rhodamine images (C). Arrows show monocytes. D-G show merged images of HUVECs and
adherent monocytes. HUVECs were treated with phosphate buffered saline as a control (D), vascular endothelial growth factor (VEGF; E),
pigment epithelial growth factor (PEDF; F), and both VEGF and PEDF (G). H shows quantification of adherent monocytes. Administration of
PEDF did not significantly alter the number of adherent monocytes compared to that of controls. Alternatively, when VEGF was added, the
number of adherent monocytes was significantly increased (p<0.01). On the other hands, when PEDF was jointly administered with VEGF,
the increase of adherent monocytes induced by VEGF was significantly reduced (p<0.01). I shows the effects of PEDF on adherent monocytes
induced by VEGF. PEDF appeared to inhibit the increase of adherent monocytes induced by VEGF in dose dependent manner. Results
represent the average of eight experiments±SEM. The data were analyzed by ANOVA with Fisher’s LSD. Double asterisks indicate p<0.01.
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